Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open

被引：0
|
作者：
Allegretti, J. R. [1 ]
Gecse, K. B. [2 ]
Chiorean, M. V. [3 ]
Argollo, M. [4 ]
Guo, X. [5 ]
Lawendy, N. [5 ]
Su, C. [5 ]
Mundayat, R. [6 ]
Paulissen, J. [6 ]
Salese, L. [5 ]
Irving, P. M. [7 ]
机构：
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Univ Amsterdam, Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[3] Swedish Med Ctr, Seattle, WA USA
[4] Univ Fed Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil
[5] Pfizer Inc, Collegeville, PA USA
[6] Pfizer Inc, New York, NY USA
[7] Guys & St Thomas Hosp, IBD Unit, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P378
引用
收藏
页码：I380 / I381
页数：3
相关论文
共 29 条
  • [1] Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open
    Allegretti, J. R.
    Gecse, K. B.
    Chiorean, M. V.
    Argollo, M.
    Guo, X.
    Lawendy, N.
    Su, C.
    Mundayat, R.
    Paulissen, J.
    Salese, L.
    Irving, P. M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I380 - I381
  • [2] EFFICACY AND SAFETY OF DOSE ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH ULCERATIVE COLITIS FOLLOWING LOSS OF RESPONSE ON TOFACITINIB 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN
    Sands, Bruce E.
    Moss, Alan C.
    Armuzzi, Alessandro
    Marshall, John K.
    Lindsay, James O.
    Sandborn, William J.
    Danese, Silvio
    Tsilkos, Konstantinos
    Lawendy, Nervin
    Zhang, Haiying
    Friedman, Gary S.
    Chan, Gary
    Krichbaum, Daniel W.
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S385 - S385
  • [3] Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
    Sands, B. E.
    Moss, A. C.
    Armuzzi, A.
    Marshall, J. K.
    Lindsay, J. O.
    Sandborn, W. J.
    Danese, S.
    Tsilkos, K.
    Lawendy, N.
    Zhang, H.
    Friedman, G. S.
    Chan, G.
    Krichbaum, D. W.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S49 - S49
  • [4] Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
    Sands, B. E.
    Moss, A. C.
    Armuzzi, A.
    Marshall, J. K.
    Lindsay, J. O.
    Sandborn, W. J.
    Danese, S.
    Zeroncio, M.
    Modesto, I.
    Salese, L.
    Lawendy, N.
    Zhang, H.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S110 - S111
  • [5] EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Sands, Bruce E.
    Moss, Alan
    Armuzzi, Alessandro
    Marshall, John K.
    Lindsay, James
    Sandborn, William J.
    Danese, Silvio
    Zeroncio, Marco
    Modesto, Irene
    Salese, Leonardo
    Lawendy, Nervin
    Zhang, Haiying
    Su, Chinyu
    GASTROENTEROLOGY, 2020, 158 (06) : S1189 - S1190
  • [6] Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
    Allegretti, J. R.
    Gecse, K. B.
    Chiorean, M. V.
    Argollo, M.
    Guo, X.
    Lawendy, N.
    Su, C.
    Mundayat, R.
    Paulissen, J.
    Salese, L.
    Irving, P. M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I446 - I447
  • [7] Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
    Allegretti, J. R.
    Gecse, K. B.
    Chiorean, M. V.
    Argollo, M.
    Guo, X.
    Lawendy, N.
    Su, C.
    Mundayat, R.
    Paulissen, J.
    Salese, L.
    Irving, P. M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I446 - I447
  • [8] EFFICACY OF TOFACITINIB DOSE ESCALATION TO 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS AFTER COMPLETING MAINTENANCE THERAPY IN REMISSION AND LOSING RESPONSE: DATA FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Rubin, David T.
    Dubinsky, Marla C.
    Panes, Julian
    Wu, Deng-Chyang
    Lawendy, Nervin
    Guo, Xiang
    Lai, Chacun
    Kwok, Kenneth
    Su, Chinyu
    Salese, Leonardo
    GASTROENTEROLOGY, 2020, 158 (06) : S1195 - S1195
  • [9] Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
    Dubinsky, M. C.
    Chou, J. W.
    Su, C.
    Wang, W.
    Modesto, I.
    Guo, X.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S120 - S121
  • [10] TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAIN
    Dubinsky, Marla C.
    Chou, Jen-Wei
    Su, Chinyu
    Wang, Wenjin
    Modesto, Irene
    Guo, Xiang
    Vermeire, Severine
    GASTROENTEROLOGY, 2020, 158 (06) : S1196 - S1196
123